Effect of nebivolol on fracture healing: An experimental rat model. 2017

Hasan Metineren, and Turan Cihan Dülgeroğlu, and Mehmet Hüseyin Metineren, and Ekrem Aydın
Department of Orthopedics and Traumatology, Medical Faculty, Dumlupınar University, Turkey.

BACKGROUND Bone metabolism is a complex system, and fracture healing is one of its most important functions. Many circumstances can influence this process. Chronic drug use in elderly populations can affect bone healing, and inadequate tissue perfusion, increased free radicals and adverse drug effects can negatively influence fracture healing. Nebivolol, an anti-hypertensive drug that selectively blocks β1 receptors, effectively reduces blood pressure by inducing peripheral vasodilation. Nebivolol also exerts anti-oxidant effects by stimulating nitric oxide (NO) synthesis. Many studies show that NO protects the vascular endothelium and improves fracture healing. OBJECTIVE In this study, the histological and radiological effects of intraperitoneally administered nebivolol on fracture healing were evaluated. METHODS Twenty-one Sprague Dawley rats were divided into 3 (nebivolol 1, 2 and control) groups. Sterile nebivolol solution (1 mL = 0.017 mg nebivolol) was given to the rats in group 1 every day for 4 weeks, while the rats in nebivolol group 2 were given 2 mL per day, beginning after the production of an open, displaced unilateral femur fracture. Radiographic and histological studies were used to evaluate fracture healing. RESULTS Histological and immunohistochemical analysis showed osseous healing with woven bone at the fracture site and only minimal amounts of cartilage in nebivolol 1 and 2 groups. Radiological grading was not different between the control and the nebivolol groups. CONCLUSIONS This study suggests that nebivolol, a selective β blocker, has positive effects on fracture healing through anti-oxidative effects via the NO pathway and direct vasodilator effects.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D010012 Osteogenesis The process of bone formation. Histogenesis of bone including ossification. Bone Formation,Ossification, Physiologic,Endochondral Ossification,Ossification,Ossification, Physiological,Osteoclastogenesis,Physiologic Ossification,Endochondral Ossifications,Ossification, Endochondral,Ossifications,Ossifications, Endochondral,Osteoclastogeneses,Physiological Ossification
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005264 Femoral Fractures Fractures of the femur. Femoral Fracture,Fracture, Femoral,Fractures, Femoral
D005269 Femur The longest and largest bone of the skeleton, it is situated between the hip and the knee. Trochanter,Greater Trochanter,Lesser Trochanter,Femurs,Greater Trochanters,Lesser Trochanters,Trochanter, Greater,Trochanter, Lesser,Trochanters,Trochanters, Greater,Trochanters, Lesser
D000068577 Nebivolol A cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients. Alpha,Alpha'-(Iminobis(Methylene))bis(6-Fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol,Bystolic,Lobivon,Nebilet,Nebivolol Hydrochloride,R 67555,R-67555,Silostar,67555, R,Hydrochloride, Nebivolol,R67555
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator

Related Publications

Hasan Metineren, and Turan Cihan Dülgeroğlu, and Mehmet Hüseyin Metineren, and Ekrem Aydın
January 2022, Joint diseases and related surgery,
Hasan Metineren, and Turan Cihan Dülgeroğlu, and Mehmet Hüseyin Metineren, and Ekrem Aydın
December 2015, Iranian Red Crescent medical journal,
Hasan Metineren, and Turan Cihan Dülgeroğlu, and Mehmet Hüseyin Metineren, and Ekrem Aydın
November 2019, Injury,
Hasan Metineren, and Turan Cihan Dülgeroğlu, and Mehmet Hüseyin Metineren, and Ekrem Aydın
October 1990, Nihon Seikeigeka Gakkai zasshi,
Hasan Metineren, and Turan Cihan Dülgeroğlu, and Mehmet Hüseyin Metineren, and Ekrem Aydın
January 2022, Cirugia y cirujanos,
Hasan Metineren, and Turan Cihan Dülgeroğlu, and Mehmet Hüseyin Metineren, and Ekrem Aydın
May 2017, Experimental and therapeutic medicine,
Hasan Metineren, and Turan Cihan Dülgeroğlu, and Mehmet Hüseyin Metineren, and Ekrem Aydın
May 2007, Indian journal of experimental biology,
Hasan Metineren, and Turan Cihan Dülgeroğlu, and Mehmet Hüseyin Metineren, and Ekrem Aydın
December 2011, Eklem hastaliklari ve cerrahisi = Joint diseases & related surgery,
Hasan Metineren, and Turan Cihan Dülgeroğlu, and Mehmet Hüseyin Metineren, and Ekrem Aydın
January 2016, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons,
Hasan Metineren, and Turan Cihan Dülgeroğlu, and Mehmet Hüseyin Metineren, and Ekrem Aydın
April 2023, Joint diseases and related surgery,
Copied contents to your clipboard!